Targeted induction before immunotherapy shows limited benefi

Targeted induction before immunotherapy shows limited benefit in advanced melanoma

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed. However, findings presented at ASCO Annual Meeting suggest that individuals with elevated lactate dehydrogenase or liver metastases may benefit from the treatment regimen.

Related Keywords

Paris , France General , France , Chicago , Illinois , United States , Sunandana Chandra , Caroline Robert , Byjosh Friedman , Mindy Valcarcel , Sud University , Pfizer , Bristol Myers Squibb , Gustave Roussy Cancer Campus , Comprehensive Cancer Center , Northwestern University ,

© 2025 Vimarsana